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Abstract
Background: Optimal management of eumycetoma, a severely debilitating chronic progressive fungal infection of skin,
disseminating to bone and viscera, remains challenging. Especially, optimal antifungal treatment and duration are ill
defined.
Methodology/Principal Findings: We conducted a monocentric retrospective study of 11 imported cases of eumycetoma
treated by voriconazole or posaconazole for at least 6 months. Response to treatment was assessed through evolution of
clinical and magnetic resonance imaging (MRI). (1R3) ß-D-glucan (BG) and positron emission tomography using [18F]
fluorodeoxyglucose (PET/CT) results were also assessed. Identified species were Fusarium solani complex (n = 3); Madurella
mycetomatis, (n = 3), and Exophiala jeanselmei, (n = 1). Moreover, two coelomycetes and one phaeohyphomycetes strains
without species identification were retrieved. Serum BG and PET/CT were abnormal in 7/8 and 6/6 patients tested,
respectively. Patients received last generation azoles for a mean duration of 25.9618 months. Complete response (major
clinical and MRI improvement) was observed in 5/11 patients, partial response (minor MRI improvement or stable MRI
findings) in 5 and failure (MRI evidence of disease progression) in one, with a 73639 [6–132] months mean follow-up.
Relapse occurred in 2 patients after treatment discontinuation. Optimal outcome was associated with fungal species,
initiation of last generation triazole therapy (,65 months since first symptoms), negative serum BG and PET/CT
normalization.
Conclusions/Significance: MRI, PET/CT and serum BG appear as promising tools to assess optimal time of antifungal
treatment for eumycetoma.
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Introduction
First described in 1642 by Kaempfer in his dissertation in the
University of Leiden and then by John Gill as ‘‘Madura Foot’’ in
1842, mycetoma is a chronic progressive and pseudotumoral
granulomatous infection of skin, subcutaneous tissues and
ultimately bone or viscera caused by fungi (eumycetoma) or
bacteria (actinomycetoma) [1]. Young male adults of low
socioeconomic status particularly manual workers in poor resource
areas are the worst affected. Eumycetoma prevails in the belt that
stretches between the 15th South and 30th North parallels,
especially in Sudan and India, where drought could favors fungal
growth in plant material including acacia and cow dung. Rural
barefoot activities favor fungus transmission to human through
subcutaneous contaminated thorn pick, which then spread locally
or through the lymphatic system, and rarely through the
bloodstream [2,3].
The eumycetoma clinical triad consists in painless subcutaneous
mass, sinus formation and sero-purulent discharge that contains
grains, aggregates of the fungal hyphae [4]. Among black
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grained-mycetoma, always of fungal origin,Madurella mycetomatis
is the most prevalent causative agent [5]. Among white grained-
mycetoma, Scedosporium boydii, Acremonium falciforme and
Fusarium spp have been most frequently reported [5].
Eumycetoma is not self-healing and spontaneously leads to
severely debilitating limb lesions with severe socioeconomic
consequences [6], making it currently one of the neglected tropical
disease according to WHO [7].
Optimal management of eumycetoma remains ill defined and
mostly relies on surgery and prolonged oral first generation
antifungal treatment, when available. Indeed, surgery alone is
associated with a 10–25% relapse rate [8]. In contrast, since 1984,
itraconazole, ketoconazole and terbinafine have been evaluated in
limited open prospective trials (i.e. maximal total number of
patients recruited being 20), in association or not with surgery, and
disclosed a 70–80 % response rate, with an acceptable tolerance
after up to 24 months of therapy and less than 10% relapse [9–13].
More recently, preliminary reports mainly from non-endemic
countries using posaconazole and voriconazole have demonstrated
in vitro activity and suggested encouraging in vivo efficacy
[14–22].
In order to better assess last generation triazoles efficacy and
their minimal treatment duration, we conducted a multicentric
retrospective study from 2002 to 2013 of 11 adult patients with
eumycetoma treated by voriconazole or posaconazole for at least 6
months with a follow-up of at least 6 months at the Centre
d’Infectiologie Necker-Pasteur, Paris, France.
Methods
Ethics statement
This study was conduced in compliance with the Institutional
Review Board Paris Necker. In accordance with French law
regarding retrospective studies, oral consent was obtained from
each patient.
Patients
Through the French National Reference Center for Invasive
Mycoses and Antifungals (NRCMA, Institut Pasteur, Paris), we
retrospectively collected all adult cases of proven eumycetoma
treated with voriconazole or posaconazole for a minimum period
of 6 months and evaluated each of them at least once at the Centre
d’Infectiologie Necker-Pasteur from January 2002 to December
2013.
All patients underwent magnetic resonance imaging (MRI)
and/or positron emission tomography using [18F] fluorodeox-
yglucose (PET/CT) before recent triazoles start and then every 6
to 12 months according to physician opinion and patient
evolution. Moreover, ten CT scanner were performed among 4
patients. Six chest and abdominal CT scanner were performed in
the patient 5 with lung involvement.
A standardized form was used to collect information regarding
age, sex, origin, place of contamination, medical background,
immunodepression, date and localization of first symptoms, date
and modalities of microbiological and/or pathological diagnosis,
prior antifungal treatment and surgery, current triazole therapy,
dosage regimen, route of administration, trough serum levels and
side effects potentially attributable to one of the two tested
triazoles.
Mycological identification
Excised grains were incubated at 30uC on liquid blood agar
medium and Sabouraud glucose adding with chloramphenicol
during at least 7 days. All isolates were identified by phenotypic
methods (macroscopic and microscopic aspect on Sabouraud,
PDA and Malt extract media, growth at 37uC, determination of
conidiogenesis by using slide culture on Malt extract agar for
Exophiala sp. and Fusarium sp. isolates), and by sequencing of the
ITS and D1/D2 regions of the gene coding ribosomal RNA by
using universal primers (V9D [23]/LS266 [24] and NL1/NL4
[25] primers respectively).
(1R3) ß -D-Glucan detection in serum samples
Serum (1R3) ß -D-Glucan (BG) levels were determined with the
Fungitell test kit (Associates of Cape Cod, Inc.,Cape Cod, MA),
according to the manufacturer’s instructions. The results of a
kinetic colorimetric assay performed at 37uC were read at 405 nm
for 40 min. The BG concentrations in samples were calculated
automatically by using a calibration curve established with
standard solutions ranging from 6.25 to 100 pg/ml. This assay is
reported continuously for results between 31–500 pg/mL, and
as.500 pg/mL for values above this range. BG levels higher than
80 pg/ml were considered to be positive, as defined by the
manufacturer. Serum assays were performed in duplicate
Trough concentration of posaconazole and voriconazole
determination
A drug assay was performed for 26 samples among 8 patients
using a previously published high-performance chromatography-
UV detection method [26].
Definitions and evaluation criteria
Immunodepression included history of diabetes, cancer, chronic
renal disease, HIV infection, autoimmune disease or immunosup-
pressive therapy. Search for immune deficiency included anti-HIV
antibodies, T, B and NK lymphocytes phenotyping and protein
electrophoresis. Organ involvements were defined by abnormal
MRI or surgical appearance compatible with eumycetoma.
Osteitis was defined by T1 weighted hypointense and T2 weighted
hyperintense signal of bone.
Clinical response to treatment was assessed by a clinical score
based on the presence of pain, inflammation signs and spontane-
ous drainage. Clinical responses were classified as ‘‘major’’ defined
by a score equal to zero or ‘‘partial’’ defined by a decrease in
Author Summary
Eumycetoma is a severe chronic progressive fungal
infection of skin and ultimately bone or viscera that affect
mainly people with low economic status. Optimal treat-
ment of this condition relies on medical and often surgical
therapy and remains challenging because of lack of gold
standard therapy and high rate of relapse after treatment
discontinuation. In this retrospective study we assessed
whether modern triazoles (voriconazole and posacona-
zole) suited to eumycetoma treatment and if tailored
treatment duration, based on serial evaluation of a serum
biomarker of fungal infection (Serum (1R3) ß-D-Glucan,
(BD)), magnetic resonance imaging (MRI) or positron
emission tomography using [18F] fluorodeoxyglucose
(PET/CT) would be useful. We found that modern triazoles
were efficient treatments of eumycetoma, allowing com-
plete or partial response in 10/11 of patients, without
significant side effects. Moreover, patients with treatment
discontinuation based on normalization of BD, MRI or PET/
CT seemed to have better long-term outcome than those
with clinical cure but still abnormal BD or imaging results.
Eumycetoma and Last Generation Triazoles
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clinical score. Stable clinical response and clinical failures were
also considered. Biological response was assessed through BG
serum levels. Major, minor, stable and worsened BG responses
were defined by normalization, decreasing, unchanged or
increasing values, respectively. MRI response, based on the
Mycetoma Skin, Muscle, Bone Grading already reported [27],
was assessed by a single expert radiologist (SP) through compar-
ison of site, size and contrast enhancement of main lesions. MRI
response was notified as major, minor, stable or failure in case of
pathologic hyper T2 signal complete disappearance, improvement
by at least 50%, stability or in case of new lesions occurrence,
respectively. The presence of a ‘‘Dot in the circle’’ pattern, i.e.
conglomerate areas of small round discrete T2 weighted hyper-
intense lesions surrounded by a low-signal-intensity rim with
central dot, highly suggestive of mycetoma [27,28] was also
analyzed. PET/CT response relied on maximum Standard
Uptake Value (SUV) comparison in a single nuclear medicine
department (CM). Major, minor, stable responses and failure were
defined by negativation, improvement (more than 30% decrease),
no change (less than 30% change) or worsening (more than 30%
increase) of max SUV values, respectively.
End of treatment (EOT) time was defined as time of treatment
discontinuation or last available evaluation. EOT response was
defined as ‘‘complete response (CR)’’ in case of clinical score
negativation, and major MRI response, as ‘‘failure’’ if one of these
parameters remained unchanged or had deteriorated or as ‘‘partial
response (PR)’’ otherwise.
Risk for underdosing was defined by low posaconazole or
voriconazole trough concentration (,1 mg/mL) or obvious non-
adherence reported by the physician in charge of patient.
Statistical analysis
Continuous data were described with descriptive statistics,
including mean6SD and/or median [range] as appropriate and
categorical data with frequencies (%). Categorical data were
analyzed by univariate analysis with Fisher’s exact test as
appropriate and continuous data by nonparametric Mann-
Whitney test. Univariate analysis was used to identify factors
associated with overall complete response at end of treatment
(EOT). P #.05 was considered statistically significant. Antifungal
treatments which duration was shorter than six months were
excluded from statistical analysis. Statistical analyses involved use
of SPSS software.
Results
Patients
Eleven cases of proven eumycetoma were identified during the
study period (Table 1). Median age at the time of first symptoms
was 28.8 [10.0–56.3] years. All patients were from African descent
(Senegal, n = 3, Mali, n = 2, Brazil, Martinique, Tchad, Maur-
itania, Togo, and Mayotte, n = 1 each), native from Western or
Central Africa (8/11). All but one patient had been likely
contaminated in Western or Central Africa, and 4/11 reported
a preceding trauma with thorn or stone. Initial sites of lesion were
mainly foot or ankle (9/11). Secondary skin and soft tissue
infection was reported in 3/11 patients. Because of debilitating
progression of the disease, 5/11 patients had to leave their job.
At diagnosis, most of them (6/11) had cardiovascular risk factor,
mainly hypertension. Two patients had chronic HBV infection
and 4 patients type II diabetes or chronic kidney disease. HIV
serology was negative, gammaglobulin serum levels and T, B, NK
lymphocytes counts were normal in all patients. Consanguinity
was present in 3/11 patients.
Diagnosis
Diagnosis was established in France in all but one patient with a
median time of 58 [7–318] months since first symptoms. Grains,
mostly of black color (8/11) were seen in every histopathological
examination thereby confirming mycetoma. Microscopic exami-
nation and mycological culture were positive in 7/11 and 10/11
cases, respectively. Identification was possible to the species level in
7/10 cases, through exclusive phenotypic methods in 4 cases
(Fusarium solani complex, n = 2; Madurella mycetomatis, n = 2)
and ITS 1/2 sequencing in 3 cases (Madurella mycetomatis, n = 1;
Fusarium solani complex, n = 1; Exophiala jeanselmei, n = 1). In 4
cases, identification was only possible to the class level of
Coelomycetes (patient 7 and 11), and Phaeohyphomycetes (patient
1 and 3). Coelomycetes class identification relied on ITS 1/2
sequencing. Phaeohyphomycete class identification relied on the
presence of pigmented molds on microscopic histopathological
examination, with negative cultures (patient 3) and phenotype
analysis of colonies with inconclusive ITS 1/2 sequencing results
(patient 1).
Prior treatments
Before last generation azole therapy, 5 patients had already
received antifungal treatments such as ketoconazole (n= 4),
itraconazole (n= 2), fluconazole or terbinafine (n= 1, each) (see
Table 2). Primary clinical failure had occurred with fluconazole, or
with shorter than 3 months treatment regimens. Eight patients had
already undergone a surgical lesion resection that induced median
clinical remission duration of 162 [19–288] months before relapse.
Evaluation at the time of voriconazole or posaconazole
initiation
At the time of initiation of last generation triazoles, all patients
were symptomatic and had pain due to osteitis, local inflammation
or purulent discharge (see Table 2 and Figure 1). MRI was
abnormal in all 11 cases, showing soft tissue, osteolytic bone
(mainly talus, calcaneus and metatarsal), muscle, articular and
visceral lesions (lung, diaphragm and kidney) in 11, 8, 5, 4 and 1/
11 cases respectively. A ‘‘dot in the circle’’ pattern was noticed in
soft tissue in 7/11 cases (picture 3A). Serum BG was tested in 8/11
cases and was positive in 7/8 cases (median value 305 [80–500]
pg/ml; normal,80 pg/ml)). There was no correlation between
BG value, lesion size evaluated by MRI or CT scanner nor SUV
max. All 6 patients studied had abnormal PET/CT with a median
SUV max of 6.6 [4.9–15.2].
Last generation triazole and surgical treatment
Last generation triazoles were initiated as primary therapy
(n= 8) or as secondary therapy following failure from prior
treatment (n = 3) (see Table 2). 6/11, 3/11 and 2/11 patients were
treated with voriconazole (200 to 350 mg BID outside meals),
posaconazole (400 mg BID with food) or switch from posacona-
zole to voriconazole for failure, respectively. Three patients were
treated with combination antifungal therapy including terbinafine
(n = 2) or flucytosine (n = 1). Additional small eumycetoma surgical
excision was performed in 5/11 patients. At last evaluation, after a
mean and median uninterrupted duration of 22.2618.3 and 18
months respectively, treatment had been discontinued for com-
pletion or toxicity in 5/11 and 1/11 patients, respectively, or was
ongoing in 5 cases.
Response to treatment and side effects
EOT response was complete, partial and null in 5/11 (45.4%),
5/11 (45.4%) and 1/11 (9.1%) patients, respectively (see Table 2
Eumycetoma and Last Generation Triazoles
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and Figure 2 and 3). Among partial responders, 3/5 had a
negative clinical score and 2/5 still complained of pain. All 3
patients with negative clinical score had minor MRI improvement
or stable MRI findings. The patient with failure had stable clinical
score but MRI evidence of progression of mycetoma to lung and
paraspinal region. Complete responders (CR) received at least 9
months of uninterrupted last generation azole treatment. Six
patients whose triazoles treatment was discontinued had a mean
follow up of 73639 [6–132] months. Among them, relapse
occurred in 2 patients, 8 and 11 months after treatment
discontinuation, respectively.
EOT major clinical, MRI, PET/CT and BG responses were
achieved in 8/11, 4/9, 4/8 and 2/6 cases, respectively after a
mean duration of triazole therapy of 25.9618.0 months. In all
patients, slight MRI contrast enhancement persisted in soft tissue
at last evaluation.
Side effects were reported in 3/11 patients treated with
voriconazole and included chronic cholestatic hepatitis, transitory
visual disturbance (related to high voriconazole trough of 5.1 mg/
mL) and muscle pain with CPK elevation. Of note, none of the
patients presented skin lesion, pain suggestive of fluorosis or
significant drug-to-drug interaction.
Comparison of patients with complete and partial or
failure responses
CR slightly differed from non-CR regarding patient’s history,
eumycetoma disease or treatment related characteristics. CR
patients tended to be older at first symptoms (median age of 40.6
years [10–56.3] and 22.5 years [18–31], respectively, p = 0.13) and
more often naive of antifungal treatment (5/5 (100%) and 3/6
(50%) patients, respectively, p = 0.38). CR presented a trend
towards earlier diagnosis of eumycetoma (median time to diagnosis
36 [7–268] and 90.0 [36–318] months respectively, p = 0.18),
earlier last generation azole treatment (median time to new azole
treatment of 65 [9–290] and 267 [114–515] months respectively,
p = 0.13) and more combination therapies (2/5 (40%) and 1/6
(16.7%) patients respectively, p = 0.38). None of CR patients was
infected with Fusarium solani or unidentified black fungi, whereas
5/6 (83.3%) of non-CR were infected with one of those species or
unidentified black fungi (p,0.05). Frequent lack of fructification of
collected strains explained difficulties to obtain readable MIC
values for all patients. MIC values were available in 5 patients, 3
with CR and 2 with PR. Patients with CR tend to have been
infected with a fungus exhibiting lower triazole MIC values than
those found in patients with PR or failure (median and range MIC
0.125 mg/L [0.014–8] and 6 mg/L [4–8], respectively, p = 0.4)
Remembering the small population size described here, patients
only treated with posaconazole had nevertheless a higher rate of
complete response than that found in other patients (3/3 (100%) vs
2/8 (25%) respectively, p = 0.06). CR received longer duration of
uninterrupted last generation azole treatment (30623.6 and
15.7610.6 months, respectively, p = 0.18). CR also had less azole
under dosage risk factors (1/5 (20%) and 4/6 (66.7%) respectively,
p = 0.24). EOT BG and PET/CT major responses were
associated with complete response at EOT (p= 0.06 and p,0.05
respectively). All of the two relapses occurred in the 2 non-CR
patients and consisted in local inflammatory signs reappearance
occurring after a mean duration of triazoles therapy of 2164.2
months.
Discussion
In this retrospective monocentric study, we describe detailed
clinical, biological, MRI and PET/CT responses of eleven patients
with eumycetoma treated by a last generation triazole in Paris.
Despite obvious limitations due to the design and small sample
size, it is to the best of our knowledge the largest reported case
series of eumycetoma treated with last generation antifungal
triazoles and the first to assess the contribution of fungal
biomarkers and MRI PET/CT in eumycetoma evaluation.
Complete or partial response was observed in 10/11 patients
treated with last generation triazoles with or without additional
surgery. This result is in agreement with previously limited
published data showing 83% (5/6) complete or partial response
rate reported with last generation triazoles in the literature [17].
Interestingly, the only case qualified as non-responder (patient 5)
was the one with the most severe visceral involvement due to
Madurella mycetomatis. Success of modern triazole despite failure
of previous azole treatments might be explained by the fact that
voriconazole has been shown in vitro to be less susceptible to
melanin binding than other antifungals and therefore more
bioavailable [29].
Figure 1. Organ involvement in patients 4 and 5. Lumbar
tumefaction with draining sinuses (A). Black grains drainage (B).
Paraspinal abdominal eumycetoma extension on abdomen MRI LAVA
sequence (C) and lung extension on lung CT scanner (D) in patient 5.
Clinical (E) second and third metatarsal destruction on 3D reconstruc-
tion CT (F) of foot. Foot mycetoma aspect on Axial T1 Fat Sat
Gadolinium MRI (G) and PET/CT (H) in patient 4.
doi:10.1371/journal.pntd.0003232.g001
Figure 2. Major MRI Response in patient 2. Major MRI response in
Patient 2 with disappearance of periachillean tissular infiltration and of
talus bone edema. Slight talus contrast enhancement persistance on T1
Gado Fat Sat sequence.
doi:10.1371/journal.pntd.0003232.g002
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In previous studies, longer treatment duration and absence of
history of disease recurrence were reported as significant predictors of
increased odds of cure from eumycetoma [30]. Here, those with
complete response were also more often naive of azole treatment and
had a trends toward a longer median treatment duration, of at least 9
months. Moreover, our results emphasize the need to shorten time to
diagnosis and deliver prolonged and uninterrupted treatment with
optimal observance and therapeutic drug monitoring (TDM). TDM
has already been shown to reduce drug discontinuation due to
adverse events and improve treatment response in invasive fungal
infections [31,32]. Finally, PR or failure tended to be associated with
Fusarium solani complex sp, higherMIC of triazole and voriconazole
vs. posaconazole use. Whether these findings reflect higher virulence
of certain fungal species and/or suboptimal pharmacokinetic-
pharmacodynamic end points achievement remains unclear. How-
ever, posaconazole is known to exhibit lower MIC values than
voriconazole against Fusarium sp [33], M. mycetomatis [20] and E.
janselmei [34] which might partly explains these results.
Both early diagnosis of mycetoma and recognition of its fungal
or bacterial origin are critical [6]. While subtle differences in
inflammation, speed pace, grain color or radiologic pattern of
bone lesions have already been reported, early distinction between
eumycetoma and actinomycetoma remains challenging [2,27].
Here, the ‘‘dot in the circle’’ pattern was present in 7/11 patients
and was already reported as an early sensitive and very specific
MRI pattern of eumycetoma and actinomycetoma [27,28]. BG is
a cell wall component of most fungal species. It has been reported
as an interesting tool for early diagnosis of invasive fungal
infections in patients with haematological malignancies [35] and
Pneumocystis jirovecii pneumonia [36]. Importantly, serum BG
was positive in 7/8 studied, suggesting its potential diagnostic role
to discriminate eumycotic and actinomycotic mycetoma, if
performed before surgery.
Interestingly, none of the complete responders relapsed during a
mean of 73 months follow up. We therefore suggest to take into
account not only clinical parameters, but also MRI features before
treatment discontinuation as clinical assessment alone was unable
to appropriately classify responders, 50% of patients without
symptom still having abnormal MRI. Moreover, patients with
serum BG or PET/CT major responses also had significantly
more chance to achieve a sustained complete response, without
relapse. We and others already reported the contribution of serum
BG and TEP TDM for follow up of invasive yeast or mold fungal
infections [37,38]. Specific contribution of these tools to customize
last generation triazole therapy duration in eumycetoma remains
however ill defined and will require prospective studies. Unfortu-
nately, modern triazoles, as MRI or PET/CT are currently too
expensive to be largely used in the context of low-income
countries. However, prospective validation of the value of negative
BD results for eumycetoma long term cure and safe treatment
discontinuation would be a major breaktrough in eumycetoma
care and would deserve larger diffusion of this cheaper technique.
Overall tolerance of long-term last generation triazoles was
good. Long-term voriconazole prescription has been associated
with phototoxicity involving acute skin lesions followed by actinic
keratosis and ultimately squamous cell cancer [39]. In our study,
with cumulative voriconazole therapy of 27.1630.5 months, no
skin lesion was noticed. Black skin phototype, absence of
immunosuppression, and shorter mean duration could explain
the absence of cutaneous side effects observed during their careful
dermatologic monitoring. In addition, fluoride excess and
periostitis have been reported in transplant and hematological
patients receiving long-term voriconazole therapy, but not with
other fluorinated triazole [40–43]. In the present study, no case of
musculoskeletal pain, PET/CT hypermetabolism, apparent peri-
ostitis or exostoses was noticed. Probably due to the efficacy of the
Figure 3. Major MRI and PET/CT responses in Patient 9. Left foot T1 Fat Sat Gadolinium enhanced MRI (A): Disappearance of periachillean
tissular infiltration with the dot in the circle pattern, talus bone edema disappearance and slight talus contrast enhancement persistence.
Disappearance of talus and tarsal hypermetabolism on left foot PET/CT (B).
doi:10.1371/journal.pntd.0003232.g003
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new therapeutics used in this study and the resulting improvement
of patient’s condition, the loss to follow up in our series was only
3/11, contrasting with 50% rate reported in the literature [30].
Conclusion
Eumycetoma remains one of the most neglected infectious
diseases around the world. In high-income countries, imported
eumycetoma frequently presents as a severe and unknown disease,
which optimal management by trained specialists should now
relies on one of the last generation triazoles, posaconazole or
voriconazole, that unfortunately aren’t available yet in endemic
countries. Beyond essential basic pharmacokinetic patients expla-
nations, optimal use of these drugs should include personalized
dosage adapted to therapeutic drug monitoring results and at least
a 9-month duration based on clinical, BG, MRI and PET/CT
follow up assessment before discontinuation.
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